Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.
Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback